Patent Claims


1) Pharmaceutical compositions characterised in that they contain one or more anticholinergics (**1**) combined with one or more dopamine agonists (**2**), optionally in the form of the enantiomers, mixtures of the enantiomers or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient.

2) Pharmaceutical composition according to claim 1, characterised in that the active substances **1** and **2** are present either together in a single formulation or in two separate formulations.

3) Pharmaceutical composition according to one of claims 1 and 2, characterised in that **1** is selected from the group consisting of tiotropium salts, oxitropium salts or ipratropium salts.

4) Pharmaceutical composition according to one of claims 1 to 3, characterised in that **1** is present in the form of the chloride, bromide, iodide, methanesulphonate or paratoluene sulphonate, preferably in the form of the bromide.

5) Pharmaceutical composition according to one of claims 1 to 4, characterised in that 2 is selected from among bromocriptin, cabergolin, alpha-dihydroergocryptin, lisuride, pergolide, pramipexol, roxindol, ropinirol, talipexol, terguride and the 7-(2-aminoethyl)-benzothiazolones of general formula 3



3

wherein

X and Y	which may be identical or different denote $-S(O)_n-$ or $-O-$;
n	denotes 0, 1 or 2;
p, q and r	which may be identical or different denote 2 or 3;
Z	denotes phenyl, which may optionally be substituted by a group selected from among halogen, $-OR^1$, NO_2 or NR^2R^3, or a 5- or 6-membered heterocycle containing N, O or S;
R^1, R^2 and R^3	which may be identical or different denote hydrogen or C_1-C_6-alkyl.

6) Pharmaceutical composition according to one of claims 1 to 5, characterised in that 2 is selected from among bromocriptin, cabergolin, alpha-dihydroergocryptin, lisuride, pergolide, pramipexol, roxindol, ropinirol, terguride, talipexol and viozan.

7) Pharmaceutical composition according to one of claims 1 to 6, characterised in that the weight ratios of **1** to **2** are in the range from 1:300 to 50:1, preferably from 1:250 to 40:1.

8) Pharmaceutical composition according to one of claims 1 to 7, characterised in that a single application corresponds to a dosage of the active

substance combination **1** and **2** of 0.1 to 10000µg, preferably from 0.1 to 2000µg.

9) Pharmaceutical composition according to one of claims 1 to 8, characterised in that it is present in the form of a formulation suitable for inhalation.

10) Pharmaceutical composition according to claim 9, characterised in that it is a formulation selected from among inhalable powders, propellant-containing metering aerosols and propellant-free inhalable solutions or suspensions.

11) Pharmaceutical composition according to claim 10, characterised in that it is an inhalable powder which contains **1** and **2** in admixture with suitable physiologically acceptable excipients selected from among the monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, or mixtures of these excipients with one another.

12) Inhalable powder according to claim 11, characterised in that the excipient has a maximum average particle size of up to 250µm, preferably between 10 and 150µm.

13) Capsules, characterised in that they contain an inhalable powder according to claim 11 or 12.

14) Pharmaceutical composition according to claim 10, characterised in that it is an inhalable powder which contains only the active substances **1** and **2** as its ingredients.

15) Pharmaceutical composition according to claim 10, characterised in that it is a propellant-containing inhalable aerosol which contains **1** and **2** in dissolved or dispersed form.

16) Propellant-containing inhalable aerosol according to claim 15, characterised in that it contains, as propellant gas, hydrocarbons such as n-propane, n-butane or isobutane or halohydrocarbons such as preferably fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.

17) Propellant-containing inhalable aerosol according to claim 16, characterised in that the propellant gas is TG134a, TG227 or a mixture thereof.

18) Propellant-containing inhalable aerosol according to claim 15, 16 or 17, characterised in that it optionally contains one or more other ingredients selected from among cosolvents, stabilisers, surfactants, antioxidants, lubricants and means for adjusting the pH.

19) Propellant-containing inhalable aerosol according to one of claims 15 to 18, characterised in that it may contain up to 5 wt.-% of active substance **1** and/or **2**.

20) Pharmaceutical composition according to claim 10, characterised in that it is a propellant-free inhalable solution or suspension which contains water, ethanol or a mixture of water and ethanol as solvent.

21) Inhalable solution or suspension according to claim 20, characterised in that the pH is 2 - 7, preferably 2 - 5.

22) Inhalable solution or suspension according to claim 21, characterised in that the pH is adjusted by means of an acid selected from among hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid or mixtures thereof.

23) Inhalable solution or suspension according to one of claims 20 to 22, characterised in that it optionally contains other co-solvents and/or excipients.

24) Inhalable solution or suspension according to claim 23, characterised in that it contains as co-solvents ingredients which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.

25) Inhalable solution or suspension according to one of claims 23 or 24, characterised in that it contains as excipients surfactants, stabilisers, complexing agents, antioxidants and/or preservatives, flavourings, pharmacologically acceptable salts and/or vitamins.

26) Inhalable solution or suspension according to claim 25, characterised in that it contains as complexing

agent editic acid or a salt of editic acid, preferably sodium edetate.

27) Inhalable solution or suspension according to claim 25 or 26, characterised in that it contains, as antioxidants, compounds selected from among ascorbic acid, vitamin A, vitamin E and tocopherols.

28) Inhalable solution or suspension according to claim 25, 26 or 27, characterised in that it contains as preservatives compounds selected from cetyl pyridinium chloride, benzalkonium chloride, benzoic acid and benzoates.

29) Inhalable solution or suspension according to one of claims 23 to 28, characterised in that it contains, in addition to the active substances **1** and **2** and the solvent, only benzalkonium chloride and sodium edetate.

30) Inhalable solution or suspension according to one of claims 23 to 28, characterised in that it contains, in addition to the active substances **1** and **2** and the solvent, only benzalkonium chloride.

31) Inhalable solution or suspension according to one of claims 20 to 30, characterised in that it is a concentrate or a sterile ready-to-use inhalable solution or suspension.

32) Use of a capsule according to claim 13 in an inhaler, preferably in a Handyhaler.

33) Use of an inhalable solution according to one of claims 20 to 30 for nebulising in an inhaler

according to WO 91/14468 or an inhaler as described in Figures 6a and 6b of WO 97/12687.

34) Use of an inhalable solution according to claim 31 for nebulising in an energy-operated free-standing or portable nebuliser which produced inhalable aerosols by means of ultrasound or compressed air according to the Venturi principle or other principles.

35) Use of a composition according to one of claims 1 to 31 for preparing a medicament for treating inflammatory or obstructive diseases of the respiratory tract.